These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24496001)

  • 1. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
    Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
    J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
    Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
    Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.
    Canon J; Bryant R; Roudier M; Osgood T; Jones J; Miller R; Coxon A; Radinsky R; Dougall WC
    Bone; 2010 Jun; 46(6):1613-9. PubMed ID: 20215062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
    Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
    J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
    Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
    Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
    Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
    PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
    Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
    BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
    Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
    Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.
    Kim HJ; Park J; Lee SK; Kim KR; Park KK; Chung WY
    J Pathol; 2015 Dec; 237(4):520-31. PubMed ID: 26239696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
    Uehara H; Takahashi T; Izumi K
    Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
    Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.